company background image
2216 logo

Broncus Holding SEHK:2216 Stock Report

Last Price

HK$0.59

Market Cap

HK$311.0m

7D

-11.9%

1Y

-62.2%

Updated

23 Mar, 2024

Data

Company Financials +

Broncus Holding Corporation

SEHK:2216 Stock Report

Market Cap: HK$311.0m

2216 Stock Overview

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally.

2216 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Broncus Holding Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Broncus Holding
Historical stock prices
Current Share PriceHK$0.59
52 Week HighHK$1.97
52 Week LowHK$0.58
Beta0.90
1 Month Change-23.38%
3 Month Change-11.94%
1 Year Change-62.18%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.07%

Recent News & Updates

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Mar 21
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Nov 30
Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Recent updates

We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Mar 21
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully

Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Nov 30
Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans

Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

May 31
Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?

Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

Feb 27
Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth

An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Dec 06
An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued

Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Sep 04
Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers

Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Jun 21
Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation

Shareholder Returns

2216HK Medical EquipmentHK Market
7D-11.9%-2.3%-0.7%
1Y-62.2%-48.6%-13.4%

Return vs Industry: 2216 underperformed the Hong Kong Medical Equipment industry which returned -48.6% over the past year.

Return vs Market: 2216 underperformed the Hong Kong Market which returned -13.4% over the past year.

Price Volatility

Is 2216's price volatile compared to industry and market?
2216 volatility
2216 Average Weekly Movement7.9%
Medical Equipment Industry Average Movement7.9%
Market Average Movement7.3%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 2216's share price has been volatile over the past 3 months.

Volatility Over Time: 2216's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012314Hong Xuhttps://www.broncus.com

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy.

Broncus Holding Corporation Fundamentals Summary

How do Broncus Holding's earnings and revenue compare to its market cap?
2216 fundamental statistics
Market capHK$311.05m
Earnings (TTM)-HK$208.88m
Revenue (TTM)HK$89.39m

3.5x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2216 income statement (TTM)
RevenueUS$11.43m
Cost of RevenueUS$2.55m
Gross ProfitUS$8.88m
Other ExpensesUS$35.59m
Earnings-US$26.71m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 28, 2024

Earnings per share (EPS)-0.051
Gross Margin77.69%
Net Profit Margin-233.68%
Debt/Equity Ratio0.01%

How did 2216 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.